Cargando…

Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum

OBJECTIVES: In the Gambia, the combination of chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) has replaced CQ monotherapy for treatment of malaria caused by Plasmodium falciparum. We measured the efficacy of the combination CQ/SP, and the prevalence of parasites carrying alleles associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunyo, Samuel, Ord, Rosalynn, Hallett, Rachel, Jawara, Musa, Walraven, Gijs, Mesa, Eduardo, Coleman, Rosalind, Sowe, Maimuna, Alexander, Neal, Targett, Geoffrey A. T, Pinder, Margaret, Sutherland, Colin J
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1513406/
https://www.ncbi.nlm.nih.gov/pubmed/16871319
http://dx.doi.org/10.1371/journal.pctr.0010014
_version_ 1782128493958529024
author Dunyo, Samuel
Ord, Rosalynn
Hallett, Rachel
Jawara, Musa
Walraven, Gijs
Mesa, Eduardo
Coleman, Rosalind
Sowe, Maimuna
Alexander, Neal
Targett, Geoffrey A. T
Pinder, Margaret
Sutherland, Colin J
author_facet Dunyo, Samuel
Ord, Rosalynn
Hallett, Rachel
Jawara, Musa
Walraven, Gijs
Mesa, Eduardo
Coleman, Rosalind
Sowe, Maimuna
Alexander, Neal
Targett, Geoffrey A. T
Pinder, Margaret
Sutherland, Colin J
author_sort Dunyo, Samuel
collection PubMed
description OBJECTIVES: In the Gambia, the combination of chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) has replaced CQ monotherapy for treatment of malaria caused by Plasmodium falciparum. We measured the efficacy of the combination CQ/SP, and the prevalence of parasites carrying alleles associated with resistance to CQ or SP. DESIGN: We conducted a single-blind, randomised, controlled trial to compare the efficacy of CQ/SP to that of SP or CQ alone. SETTING: The study took place in the town of Farafenni and surrounding villages in the Gambia. PARTICIPANTS: Participants were children aged 12 mo to 10 y presenting as outpatients with uncomplicated P. falciparum malaria. INTERVENTIONS: 500 children were randomised to receive CQ, SP, or CQ/SP as supervised treatment and actively followed over 28 d. OUTCOME MEASURES: Primary outcome was parasitaemia at any time during follow-up. Secondary outcomes were PCR-confirmed recrudescent infections among treatment failures, and clinical failure requiring rescue medication by day 28. Pretreatment parasite isolates from 161 patients were tested for the presence of resistance-associated genetic markers. RESULTS: The prevalence of parasitological failure by day 28 for the CQ group was 60.3%, compared to 17.6% for SP (odds ratio [OR], 0.106; 95% confidence interval [CI], 0.057–0.194; p < 0.001) and 13.9% for CQ/SP (OR versus CQ, 0.140; 95% CI, 0.078–0.250; p < 0.001). There was no difference between the SP and CQ/SP groups (OR, 1.324; 95% CI, 0.705–2.50). The projected prevalence of PCR-corrected treatment failure was 30.2, 6.06, and 3.94% in the CQ, SP, and CQ/SP groups, respectively. The pfdhfr-triple mutant and pfdhps-437G mutation were common, with prevalences of 67.4 and 51.2%, respectively. Pretreatment carriage of pfdhps-437G and of multidrug-resistant parasite genotypes was associated with treatment failure in the SP group, but not in the CQ or CQ/SP groups. CONCLUSIONS: The combination of CQ/SP was an efficacious treatment for uncomplicated malaria in Gambian children in this study, but the frequent occurrence of multidrug-resistant parasites suggests that this observed efficacy is not sustainable.
format Text
id pubmed-1513406
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-15134062007-04-12 Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum Dunyo, Samuel Ord, Rosalynn Hallett, Rachel Jawara, Musa Walraven, Gijs Mesa, Eduardo Coleman, Rosalind Sowe, Maimuna Alexander, Neal Targett, Geoffrey A. T Pinder, Margaret Sutherland, Colin J PLoS Clin Trials Research Article OBJECTIVES: In the Gambia, the combination of chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) has replaced CQ monotherapy for treatment of malaria caused by Plasmodium falciparum. We measured the efficacy of the combination CQ/SP, and the prevalence of parasites carrying alleles associated with resistance to CQ or SP. DESIGN: We conducted a single-blind, randomised, controlled trial to compare the efficacy of CQ/SP to that of SP or CQ alone. SETTING: The study took place in the town of Farafenni and surrounding villages in the Gambia. PARTICIPANTS: Participants were children aged 12 mo to 10 y presenting as outpatients with uncomplicated P. falciparum malaria. INTERVENTIONS: 500 children were randomised to receive CQ, SP, or CQ/SP as supervised treatment and actively followed over 28 d. OUTCOME MEASURES: Primary outcome was parasitaemia at any time during follow-up. Secondary outcomes were PCR-confirmed recrudescent infections among treatment failures, and clinical failure requiring rescue medication by day 28. Pretreatment parasite isolates from 161 patients were tested for the presence of resistance-associated genetic markers. RESULTS: The prevalence of parasitological failure by day 28 for the CQ group was 60.3%, compared to 17.6% for SP (odds ratio [OR], 0.106; 95% confidence interval [CI], 0.057–0.194; p < 0.001) and 13.9% for CQ/SP (OR versus CQ, 0.140; 95% CI, 0.078–0.250; p < 0.001). There was no difference between the SP and CQ/SP groups (OR, 1.324; 95% CI, 0.705–2.50). The projected prevalence of PCR-corrected treatment failure was 30.2, 6.06, and 3.94% in the CQ, SP, and CQ/SP groups, respectively. The pfdhfr-triple mutant and pfdhps-437G mutation were common, with prevalences of 67.4 and 51.2%, respectively. Pretreatment carriage of pfdhps-437G and of multidrug-resistant parasite genotypes was associated with treatment failure in the SP group, but not in the CQ or CQ/SP groups. CONCLUSIONS: The combination of CQ/SP was an efficacious treatment for uncomplicated malaria in Gambian children in this study, but the frequent occurrence of multidrug-resistant parasites suggests that this observed efficacy is not sustainable. Public Library of Science 2006-07-21 /pmc/articles/PMC1513406/ /pubmed/16871319 http://dx.doi.org/10.1371/journal.pctr.0010014 Text en © 2006 Dunyo et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Dunyo, Samuel
Ord, Rosalynn
Hallett, Rachel
Jawara, Musa
Walraven, Gijs
Mesa, Eduardo
Coleman, Rosalind
Sowe, Maimuna
Alexander, Neal
Targett, Geoffrey A. T
Pinder, Margaret
Sutherland, Colin J
Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum
title Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum
title_full Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum
title_fullStr Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum
title_full_unstemmed Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum
title_short Randomised Trial of Chloroquine/Sulphadoxine-Pyrimethamine in Gambian Children with Malaria: Impact against Multidrug-Resistant P. falciparum
title_sort randomised trial of chloroquine/sulphadoxine-pyrimethamine in gambian children with malaria: impact against multidrug-resistant p. falciparum
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1513406/
https://www.ncbi.nlm.nih.gov/pubmed/16871319
http://dx.doi.org/10.1371/journal.pctr.0010014
work_keys_str_mv AT dunyosamuel randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum
AT ordrosalynn randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum
AT hallettrachel randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum
AT jawaramusa randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum
AT walravengijs randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum
AT mesaeduardo randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum
AT colemanrosalind randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum
AT sowemaimuna randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum
AT alexanderneal randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum
AT targettgeoffreyat randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum
AT pindermargaret randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum
AT sutherlandcolinj randomisedtrialofchloroquinesulphadoxinepyrimethamineingambianchildrenwithmalariaimpactagainstmultidrugresistantpfalciparum